OHSU

IRB #

IRB00010053

Title

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment with Disease-Modifying Antirheumatic Drugs

Principal Investigator

Cong-Qiu Chu

Study Purpose

To investigate the efficacy and safety of a study drug called baricitinib when used to treat severe active Rheumatoid Arthritis (RA) in those with limited or no experience with methotrexate (MTX)

Medical Condition(s)

Moderate to Severe Active Rheumatoid Arthritis (RA)

Eligibility Criteria

Males and Females, age 18 and older, with RA who have had little to no experience with methotrexate (MTX)

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Males and Females, age 18 and older, with RA who are currently taking and having an inadquate response to methotrexate

Minors Included

No

Contact

Margaret Sels or Brenda Olmos
503.494.5742 or 503.498.1065

Sponsor

Eli Lilly & Company

Recruitment End

12/26/2014

Compensation Provided

Yes

Compensation

Subjects will receive $42 for each study visit completed. The total amount they could receive will greatly depend on how long they stay in the study.


Go Back